Maury Raycroft
Stock Analyst at Jefferies
(1.28)
# 3,655
Out of 5,022 analysts
49
Total ratings
28.95%
Success rate
-9.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KOD Kodiak Sciences | Initiates: Buy | $15 | $12.48 | +20.19% | 1 | Sep 22, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $328 → $384 | $469.36 | -18.19% | 2 | Jul 7, 2025 | |
| CRDF Cardiff Oncology | Initiates: Hold | $3.5 | $2.27 | +54.19% | 1 | Jun 24, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $16.25 | +226.15% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $4.34 | +84.33% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.69 | +336.94% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $1.96 | +257.14% | 1 | Dec 6, 2024 | |
| ERAS Erasca | Initiates: Buy | $6 | $2.41 | +148.96% | 1 | Nov 18, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $8.70 | +118.39% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $5.99 | +150.42% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $39 | $35.55 | +9.72% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.79 | +655.95% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $2.90 | +693.10% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $11.83 | +1,548.35% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $6.42 | +71.34% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $30.30 | -80.20% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $35.96 | +108.57% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $8.42 | +30.64% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $13.93 | +93.90% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.63 | +206.75% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $46.20 | +3.90% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $10.41 | +245.82% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $6.23 | +1,585.39% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $69.38 | +147.91% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $3.76 | +1,150.00% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $4.33 | +5,211.78% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $23.90 | +75.73% | 3 | Nov 1, 2017 |
Kodiak Sciences
Sep 22, 2025
Initiates: Buy
Price Target: $15
Current: $12.48
Upside: +20.19%
Alnylam Pharmaceuticals
Jul 7, 2025
Maintains: Buy
Price Target: $328 → $384
Current: $469.36
Upside: -18.19%
Cardiff Oncology
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $2.27
Upside: +54.19%
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $16.25
Upside: +226.15%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $4.34
Upside: +84.33%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.69
Upside: +336.94%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $1.96
Upside: +257.14%
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $2.41
Upside: +148.96%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $8.70
Upside: +118.39%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $5.99
Upside: +150.42%
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $35.55
Upside: +9.72%
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.79
Upside: +655.95%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $2.90
Upside: +693.10%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $11.83
Upside: +1,548.35%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $6.42
Upside: +71.34%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $30.30
Upside: -80.20%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $35.96
Upside: +108.57%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $8.42
Upside: +30.64%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $13.93
Upside: +93.90%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.63
Upside: +206.75%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $46.20
Upside: +3.90%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $10.41
Upside: +245.82%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $6.23
Upside: +1,585.39%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $69.38
Upside: +147.91%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $3.76
Upside: +1,150.00%
Jul 16, 2018
Initiates: Buy
Price Target: $230
Current: $4.33
Upside: +5,211.78%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $23.90
Upside: +75.73%